Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTIS2023-510365-10-00
CTIS2023-510365-10-00RecruitingPhase 1

J4P-MC-IYAB

Eli Lilly & Co.0 sites70 target enrollmentStarted: February 26, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Enrollment
70
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 64 (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Similar Trials

Active, not recruiting
Phase 1
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancerung Cancer or Breast Cancer
CTIS2023-506788-32-00Eli Lilly & Co.1
Active, not recruiting
Phase 1
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentProstatic Neoplasms
CTIS2023-503919-15-00Eli Lilly & Co.42
Recruiting
Phase 1
A Randomised Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3876602 in Healthy Participants.HealthyMedDRA version: 21.1Level: PTClassification code: 10053643Term: Neurodegenerative disorder Class: 100000004852
CTIS2023-504838-21-00Eli Lilly & Co.69
Active, not recruiting
Phase 1
A Study of LY3200882 in Participants With Solid Tumors.Solid Tumor, Metastatic cancer
CTIS2023-507177-17-00Eli Lilly & Co.1
Completed
Not Applicable
HE4, yamamotoMdilated cardiomyopathy
JPRN-UMIN000043062Kumamoto University87